Volume | 929 |
|
|||||
News | (1) | ||||||
Day High | 26.33 | Low High |
|||||
Day Low | 25.0957 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
XOMA Corporation | XOMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
26.22 | 25.0957 | 26.33 | 26.50 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
66 | 929 | US$ 25.53 | US$ 23,714 | - | 13.48 - 27.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
10:06:39 | 4 | US$ 25.97 | USD |
XOMA Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
291.81M | 11.63M | - | 4.76M | -40.83M | -3.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
XOMA News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XOMA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 25.83 | 26.79 | 25.04 | 25.92 | 9,010 | -0.7343 | -2.84% |
1 Month | 25.46 | 27.00 | 24.00 | 25.60 | 11,926 | -0.3643 | -1.43% |
3 Months | 19.90 | 27.00 | 19.50 | 24.41 | 18,456 | 5.20 | 26.11% |
6 Months | 17.43 | 27.00 | 14.27 | 20.36 | 23,683 | 7.67 | 43.98% |
1 Year | 18.31 | 27.00 | 13.48 | 18.56 | 29,932 | 6.79 | 37.06% |
3 Years | 36.44 | 39.49 | 13.48 | 21.47 | 30,240 | -11.34 | -31.13% |
5 Years | 12.26 | 46.32 | 11.58 | 23.21 | 39,360 | 12.84 | 104.70% |
XOMA Description
XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. |